Literature DB >> 2895072

Beta-adrenergic receptor blockers. Adverse effects and drug interactions.

W H Frishman1.   

Abstract

Adverse effects of beta-adrenergic receptor blocking drugs can be divided into two categories: 1) those that result from known pharmacological consequences of beta-adrenergic receptor blockade; and 2) other reactions that do not appear to result from beta-adrenergic receptor blockade. Adverse effects of the first type include bronchospasm, heart failure, prolonged hypoglycemia, bradycardia, heart block, intermittent claudication, and Raynaud's phenomenon. Neurological reactions include depression, fatigue, and nightmares. It is not yet proven whether the beta 1-selective adrenergic blockers or those with partial agonist activity reduce the overall frequency of adverse reactions seen with propranolol. Patient age does not appear, in itself, to be associated with more beta-blocker side effects. Side effects of the second category are rare. They include an unusual oculomucocutaneous reaction and the possibility of oncogenesis. There are also many drugs that interact with beta-blockers, which may increase toxicity. Finally, there are specific patient characteristics where one beta-blocker may be more effective and safer than another.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895072     DOI: 10.1161/01.hyp.11.3_pt_2.ii21

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

1.  Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction.

Authors:  Siva Sai Krishna Dasa; Ryo Suzuki; Michael Gutknecht; Lindsey T Brinton; Yikui Tian; Erik Michaelsson; Lennart Lindfors; Alexander L Klibanov; Brent A French; Kimberly A Kelly
Journal:  J Control Release       Date:  2015-06-27       Impact factor: 9.776

2.  Hypertension in the elderly.

Authors:  Nikolaos Lionakis; Dimitrios Mendrinos; Elias Sanidas; Georgios Favatas; Maria Georgopoulou
Journal:  World J Cardiol       Date:  2012-05-26

Review 3.  Trials in isolated systolic hypertension: an update.

Authors:  Bernard Waeber
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 4.  Trials in isolated systolic hypertension: an update.

Authors:  Bernard Waeber
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

Review 5.  Management of pregnancy in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

6.  Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.

Authors:  Luca Filippi; Giacomo Cavallaro; Patrizio Fiorini; Marta Daniotti; Valentina Benedetti; Gloria Cristofori; Gabriella Araimo; Luca Ramenghi; Agostino La Torre; Pina Fortunato; Liliana Pollazzi; Giancarlo la Marca; Sabrina Malvagia; Paola Bagnoli; Chiara Ristori; Massimo Dal Monte; Anna Rita Bilia; Benedetta Isacchi; Sandra Furlanetto; Francesca Tinelli; Giovanni Cioni; Gianpaolo Donzelli; Silvia Osnaghi; Fabio Mosca
Journal:  BMC Pediatr       Date:  2010-11-18       Impact factor: 2.125

7.  S(-)Propranolol as a discriminative stimulus and its comparison to the stimulus effects of cocaine in rats.

Authors:  Richard Young; Richard A Glennon
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

8.  The Brain and Propranolol Pharmacokinetics in the Elderly.

Authors:  Andy R Eugene; Wayne T Nicholson
Journal:  Brain (Bacau)       Date:  2015-11

Review 9.  Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents.

Authors:  K Miller
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 10.  Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Authors:  Khaled Albouaini; Mohammed Andron; Albert Alahmar; Mohaned Egred
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.